Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017-02-20
Future Challenges for Drug Development in Renal Cell Carcinoma.
Related Questions
The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib.
New answer by (February 22, 2017)
Although the results from the phase II CABOSUN trial were intriquing, I would not consider cabozantinib as first line therapy for patients with intermediate or poor-...